Abstract
Background:Infliximab (IFX) is increasingly used in the management of severe, relapsing or refractory manifestations of Behçet Syndrome (BS). Emergence of de novo manifestations have been reported during IFX treatment, despite...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have